Is a low insulin response to intravenous glucose an marker of Type 1 (insulin-dependent) diabetes?
Dear Sir, Recently B. Vialettes et al. published the results of a study to determine the value of low acute insulin response to intravenous glucose as a marker of early stages of Type i (insulin-dependent) diabetes mellitus [1] .
In their article the authors raise the question, whether low acute insulin response is a reliable marker of pre Type 1 diabetes in young patients. In their conclusion they state, that a low acute insulin response to glucose is a sensitive but not specific marker of early stages of Type 1 diabetes. They based their results on a population of 39 individuals with mild or transient hyperglycaemia with fasting blood-glucose levels between 7.7 and 10.0 mmol/1 by two separate measurements. According to WHO criteria they can thus be classified as diabetic patients [2] . The population was followed for three years. They state that at the end of this period the patients were insulin-dependent. This insulin-dependency however, is not defined and seems to be nothing more than insulin treated.
In a group of 150 first degree relatives of Type I diabetic patients only two persons became diabetic. Obviously this number is too low to make a reliable estimate of sensitivity and specificity.
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The conclusion is thus only valid in diabetic patients, who may or may not be suffering from slow Type 1 diabetes. For the relatives of Type 1 diabetic patients no conclusion can be drawn at all. Response from the authors Dear Sir, We are only partly in agreement with Dr. Razenberg's statement. We readily admit that the small number of diabetic subjects appearing in our cohort of relatives of Type I (insulin-dependent) diabetic patients during the 3 years does not allow us to assert that low acute insulin response to glucose (LAIR) is a sensitive marker of evolution to Type 1 diabetes in the near future [1] . However, if one pools our two cases to the four reported by Ganda [2] and the seven by Chase [3] , it would appear that LAIR is a common feature of pre-Type 1 diabetes. With regards to the poor specificity of LAIR, we do think that our data allows this conclusion. Prevalence of LAIR is almost twice that of the theoretical risk of diabetes in this population of relatives of Type 1 diabetic patients. Obviously not all the subjects with LAIR will become diabetic in the future. Finally, our paper stresses that some relatives of Type 2 diabetic patients may also exhibit the same anomaly of the insulin response. 
Effect of ~a-adrenoceptor antagonist on platelet activation during insulin-induced hypoglycaemia in Type 2 (non-insulin-dependent) diabetes mellitus
Dear Sir, Takeda et al. [1] have established that the platelet hyperaggregability occurring during acute hypoglycaemia is mediated by elevated plasma levels of adrenaline. A few additional comments may be of interest.
The conclusions of Takeda et al. [1] are supported by the finding that the elevated plasma concentrations of ACTH, cortisol, growth hormone and prolactin that occur during acute hypoglycaemia are unlikely to activate platelets [2] [3] [4] .
Elevated plasma adrenaline concentrations may also exert poten~ tially adverse effects other than platelet activation. For example, this catecholamine induces a hypokalaemia (probably mediated by beta adrenoceptors) which may in turn increase the risk of cardiac arrhythmia [5] . Another catecholamine-dependent process which occurs during hypoglycaemia, the elevation of plasma coagulation factor VIII: RAg concentration, also appears to be at least partially dependent upon beta adrenoceptor activation [51. Furthermore, adrenaline is thought to stimulate vascular prostacyclin (a potent inhibitor of platelet aggregation) release [6] The events mentioned above may be more prominent in diabetic patients with established vascular pathology. It is not surprising therefore, that there are several reports of transient ischaemic attacks in association with acute hypoglycaemia (5). An increased incidence of this complication would be in addition to those mentioned by Takeda et al. [1] . Predicting an increased incidence of acute myocardial infarction or cardiac arrhythmia in association with acute hypoglycaemia also seems appropriate. Do the readers know of such events ?
Finally, a methodological point requires clarification. Midaglizole (2.5 Ixmol/1), inhibited thrombin-induced platelet aggregation in washed platelets. Yet this process is unlikely to be c~-adrenoceptor mediated. Furthermore, this concentration of midaglizole inhibited adrenaline-induced aggregation in platelet rich plasma (PRP) and even higher concentrations of midaglizole were shown to be agonist specific in PRP (i.e. midaglizole did not inhibit ADP-, collagen-, serotonin-or vasopressin-induced aggregation). The authors do not comment on this apparent discrepancy. We have also observed a relative lack of selectivity with a-adrenoceptor blockers. For example, yohimbine inhibited collagen-induced aggregation in PRP but the concentrations required were approximately 40-fold greater than those which inhibit adrenaline-induced aggregation (unpublished observations). There is no evidence indicating this degree of selectivity for midaglizole as far as washed platelets are concerned. Is it just a matter of differences in sensitivity between PRP and washed platelets ? 
Response from the authors
Dear Sir, We appreciate Dr. Mikhailidis and his coworker's valuable comments on our paper [1] . We would like to discuss two main points based on their comments.
The first comment is related to adverse effects of epinephrine on cardiovascular damage other than platelet activation during hypoglycaemia, such as increased plasma Factor VIII, increased incidence of cardiac arrhythmia due to hypokalaemia, myocardial infarction and transient ischaemic attacks. Firstly, we would like to emphasize that we mainly focused on the role of hypoglycaemia-induced platelet hyperaggregability in the deterioration of diabetic microangiopathy due to capillary microinfarction [1] . We think that the platelet hyperaggregability might be mainly responsible for the capillary micro-infarction because capillary vessels, which have no smooth muscle cells, are probably influenced neither by catecholamines nor by c~2-antagonists as far as we know. On the other hand, vascular stimulation induced by catecholamines and/or vasopressin [2] during hypoglycaemia may be quite important for the development of diabetic macroangiopathy as well as platelet hyperaggregability and other factors such as abnormal lipid metabolism. However, increased vascular prostacyclin release by epinephrine as pointed out by Mikhailidis et al. seems to have a beneficial effect, and decreased prostacyclin release in diabetic patients is probably produced by factors other than epinephrine and/or adrenergic receptors. Therefore, we suggest that c~2-antagonist might be a potent preventor for the deterioration of diabetic microangiopathy, but not for macroangiopathy. However, it would be valuable to investigate whether the cardiovascular damage pointed out by Mikhailidis et al. was influenced by a2-antagonist or not, because almost all of these points remain unclear.
The second comment is related to receptor selectivity of an c~2-antagonist, midaglizole, on washed platelets. Midaglizole seems to be highly selective to platelet c~2-adrenoceptor on platelet-rich plasma as described in our paper [1] as well as mianserin as reported previously [3] , On the other hand, midaglizole (2.5 ~xmol/1) weakly but significantly suppressed thrombin-induced platelet aggregation in washed platelets. Although we have not commented upon this in our present paper [1] , we think that midaglizole is az-selective on washed platelets too, based on the following reasons:
1. The concentration required to inhibit maximum platelet aggregation by 50% (ICs0) of midaglizole for the thrombin-induced aggregation (20 U/l) was 70 rimes greater (250 lxmol/1) than that for the aggregation induced by epinephrine (0.02 p~mol/1) with thrombin (15 U/l) in washed platelets (3.6 p~mol/1, unpublished data). 2. Similarly, Lanza et al. [4] demonstrated that the concentration for 50% inhibition (ICs0) of an c~-antagonist, nicergoline, for the thrombin-induced aggregation was 60 times greater than that for the aggregation induced by epinephrine with thrombin. In addition, they described similar results with adenosine 5'-diphosphate, collagen, arachidonic acid, platelet activating factor and A23187. 3. Such effects of a-antagonists on various agents other than epinephrine may be nonspecific because non-physiological high concentrations are necessary to get enough inhibition, but these might be the result of specific inhibition of (z2-adrenoceptor-mediated platelet stimuli. Some of the stimuli with thrombin [5] and epinephrine [6] are known to be commonly mediated by cyclic adenosine monophosphate and/or phospholipases. We previously reported that thrombininduced phospholipase activation in washed platelets was significantly inhibited by an adenylate cyclase activator, prostaglandin E1 [5] .
Anyway, the precise mechanisms of these phenomena remain to be clarified further.
Yours sincerely, H. Takeda, H. Kishikawa, M. Shinohara, T. Miyata, K. Suzaki, H. Fukushima, K. Ichinose and M. Shichiri
